Background The prevalence of and risk factors for neurological problems in childhood coeliac disease (CD) are unclear.
Methods We performed a cross-sectional, community-based audit of CD in children diagnosed from January 2010 to December 2016 in Lothian.
Results 79 (28%) of 284 children with CD (201, 70.8% female) (mean age 8.3 years, range of 1–16) had neurological problems. Fifteen (5%) had headaches/migraine, 3 (1%) seizures, 32 (11%) ASD (autistic spectrum disorder), 5 (2%) ADD (attention deficit disorder) and 4 (1%) had ADHD (attention deficit hyperactivity disorder). Fifteen (5%) had anxiety (n=10, 3.5%) or low mood (n=5, 2%). Neurological problems were more common with later age at CD diagnosis (OR 1.07, 95% CI 1.01 to 1.14) and male gender (OR 1.69, 95% CI 0.96 to 2.95).
Conclusion Prevalence of neurological problems in children with CD in Lothian is lower than published adult CD studies and similar or lower to the reported prevalence in the general childhood population.
Data availability statement
Data are available upon reasonable request.
Statistics from Altmetric.com
Contributors Original database work conducted by PW, DB and DP. Data analyses and prinicipal drafting of manuscript by TO'N, PG and RC. Study conceptualisation and design by PG and RFC.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.